For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells. However, success has been limited due to the technological challenge of engineering therapies that provide specific enough “training” to the immune system to identify a given patient’s neoantigens.
Medical Xpress – latest medical and health news stories
